KPTI logo

KPTI
Karyopharm Therapeutics Inc

7,801
Mkt Cap
$95.31M
Volume
56,334.00
52W High
$13.35
52W Low
$3.51
PE Ratio
-0.38
KPTI Fundamentals
Price
$5.50
Prev Close
$5.59
Open
$5.55
50D MA
$6.09
Beta
1.23
Avg. Volume
286,289.65
EPS (Annual)
-$9.41
P/B
-0.18
Rev/Employee
$520,562.72
Loading...
Loading...
News
all
press releases
Best Nuclear Stocks To Add to Your Watchlist - November 7th
Oklo, NuScale Power, Centrus Energy, BWX Technologies, Nano Nuclear Energy, Lightbridge, and Karyopharm Therapeutics are the seven Nuclear stocks to watch today, according to MarketBeat's stock...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire NEWTON...
PR Newswire·10d ago
News Placeholder
OmniAb, Inc. (OABI) Expected to Beat Earnings Estimates: Should You Buy?
OmniAb, Inc. (OABI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·16d ago
News Placeholder
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025 PR Newswire NEWTON, Mass., Oct. 27, 2025...
PR Newswire·18d ago
News Placeholder
Karyopharm Therapeutics (KPTI)'s Technical Outlook is Bright After Key Golden Cross
Is it a good or bad thing when a stock experiences a golden cross technical event?
Zacks·27d ago
News Placeholder
Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last?
Karyopharm Therapeutics (KPTI) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks·2mo ago
News Placeholder
Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates
Karyopharm Therapeutics (KPTI) delivered earnings and revenue surprises of -13.68% and -5.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Collegium Pharmaceutical (COLL) Q2 Earnings and Revenues Surpass Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of +3.70% and +4.23%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
United Therapeutics (UTHR) Misses Q2 Earnings Estimates
United Therapeutics (UTHR) delivered earnings and revenue surprises of -5.74% and +0.36%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4mo ago
News Placeholder
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Karyopharm Therapeutics (KPTI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·4mo ago

Latest KPTI News

View

Advertisement|Remove ads.

Advertisement|Remove ads.